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related to reduced tears quantity and ocular surface sensitivity, leading to inflammatory reaction. Managing the eye inflammation
proved helpful to patients with dry eye disease and current treatment is based on the use of topically applied artificial tear prod-
ucts/lubricants, tear retention management, stimulation of tear secretion and using anti-inflammatory drugs. In this article we
revise the corresponding literature and patents assembling the new treatment approaches of novel and future pharmaceutical
compounds destined for the dry eye disease treatment. The most frequent categories of compounds presented are secretagogues
and anti-inflammatory drugs. These compounds are the research outcome of novel therapeutic strategies designed to reduce key
inflammatory pathways and restore healthy tear film.
Keywords: Dry eye, Anti-inflammatory, Keratoconjunctivitis sicca, Keratitis sicca, Xerophthalmia, Mucin secretion, Tear secretion,
NSAID
 2013 Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University.
http://dx.doi.org/10.1016/j.sjopt.2013.12.003Introduction
Dry eye is a disease which starts with unpleasant levels of
symptoms of dryness of eyes and an uncomfortable feeling,
greatly preventing people from performing daily activities
when the disease worsens. The number of dry eye patients
is increasing yearly in association with the aging of the society
and the increase in VDT (video display terminal) works with
personal computers and devices. Dry eye prevalence in
2009 in Spain was 11.0% among adults. Dry eye was found
to be more frequent in women (11.9%) than in men (9.0%),
and was significantly associated with aging.1 Although exact
etiopathogenesis of dry eye is not known, it is believed that
decrease in the tear volume on the corneal and conjunctival
surface caused by either a decreased tear secretion or accel-
erated evaporation plays the main role. The clinical features
of dry eyes include ocular discomfort, feeling of dryness, feel-
ing of eye fatigue, hyperemia, keratoconjunctival epithelialdisorders and abnormalities of vision. If these symptoms
and observations progress, eventually abnormality occurs in
vision. Therefore, it is quite important to treat dry eye prop-
erly at an early stage. Wetness of the ocular surface and other
exposed mucosae is maintained by a continuous aqueous
fluid secretion produced by exocrine glands.2–4 In the eye,
basal tear flow is adjusted to variations in environmental con-
ditions and blinking rate. Tear flow occurring in the absence
of emotional or exogenous irritant stimuli (‘basal’ tear secre-
tion) is adjusted to variations in environmental conditions and
blinking rate.5 Tearing also increases markedly upon ocular
surface irritation.6 Irritating stimuli are detected by mechan-
o-nociceptor and polymodal-nociceptor trigeminal nerve
endings sensitive to injurious mechanical forces, noxious heat
and irritant chemicals, that evoke pain and irritation-induced
tearing.7 However, the neural structures responsible for
sensing ocular surface dryness to regulate basal tearing
rate remain undefined. Dry eye syndrome is a diseasee:
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20 B. Colligris et al.characterized by persistent dryness of the conjunctiva and
opacity of the cornea. Multiple causes can lead to dry eye,
which is more common in elderly people. Among diseases
causing dry eye are: vitamin A deficit, Sjögren’s syndrome,
rheumatoid arthritis and other rheumatologic diseases,
chemical or thermal burns, drugs such as atenolol, chlorphe-
niramine, hydrochlorothiazide, isotretinoin, ketorolac, ketoti-
fen, levocabastin, levofloxacin, oxybutynin, and tolterodine.Current dry eye treatment
The symptomatic relief of dry eye includes tear supple-
ments called ‘‘artificial tears’’ which are artificial lubricants,
characterized by hypotonic or isotonic buffered solutions
containing electrolytes, surfactants and various types of vis-
cosity agents.8 Another treatment option is the application
of tear retention devices. Implants are developed to perma-
nently occlude the lacrimal puncta. These kinds of implants
also known as punctal plugs, and could be absorbables and
non-absorbables.9 Additional treatment is by using moisture
chamber spectacles. It has been reported that increases in
periocular humidity can cause a growth of the lipid layer tear
film thickness and also that spectacle wearers with dry eye
have a longer inter-blink interval than those who do not wear
spectacles.10 On the pharmacology side current treatment is
mainly focusing on addressing inflammation and tear restora-
tion.11 Dry eye disease is the outcome of many factors result-
ing in inflammation of the cornea and conjunctiva. The
dysfunction of the tear secretory glands leads to changes in
tear composition such as hyper-osmolarity which stimulates
the production of inflammatory mediators on the ocular
surface. This inflammation can be initiated either by chronic
irritative stress like contact lens wearing or a systemic inflam-
matory autoimmune disease like rheumatoid arthritis.12,13
Anti-inflammatory drugs are widely used for the treatment
of the inflammation produced by the disease with the topical
corticosteroid drops being the most common therapy. Corti-
costeroids can rapidly and effectively relieve the symptoms
and signs of moderate or severe dry eye.14 Steroids on the
other hand produce severe side effects after prolonged
use. The effects include risk of bacterial or fungal infection,
elevated intraocular pressure and cataract formation, there-
fore steroids are typically used only for one to two weeks in
dry eye patients.15 As a consequence, non-steroidal anti-
inflammatory drugs (NSAID) are increasingly used as dry
eye treatment instead of steroids because of their non-severe
side effects and because steroids locally suppress the im-
mune response in patients with an already compromised ocu-
lar surface. The NSAIDs acutely decrease the eye discomfort
due to its analgesic effect and furthermore is reducing the
inflammation. In 2002 U.S. Food and Drug Administration ap-
proved the drug RESTASIS of the company Allergan as the
first prescription medicine helping to increase tear produc-
tion reduced by inflammation due to chronic dry eye disease.
Topical RESTASIS diquafosol tetrasodium is an ophthalmic
emulsion containing cyclosporine 0.05%.16 Other type of
drug used is the antibiotics including oral doxycycline, azith-
romycin, and tetracycline. There is some research on the use
of serum tears and intense pulse light treatment.17
In this review we are presenting the trends on the oncom-
ing treatments, analyzing the patents filled from the researchinstitutions. The data are represented on a table of drugs and
properties (Table 1).Recent developments
Cytokine receptor inhibitors
Cytokines are a group of hormones incapable to penetrate
through the cell membrane and functioning by binding to
cognate receptor proteins.18 Cytokines use multiple signaling
pathways with JAK-STAT pathway being the most important.
Janus kinases (JAKs) are components of the cytokine recep-
tor signaling pathway and signal transducers and activators
of transcription (STATs). After the discovery of JAK’s it was
identified as the STAT family of transcription factors
(STAT1-5a, 5b and 6).19 The activation of the cytokine recep-
tor JAK signaling complex leads to the stimulation of JAK ki-
nases resulting in the phosphorylation of receptor chains,
creating docking sites for STAT transcription factors.20 Gen-
erally, cytokine receptors do not have intrinsic tyrosine kinase
activity, and thus require receptor-associated kinases to
propagate a phosphorylation cascade. Cytokines bind to
their receptors, causing receptor dimerization, and this en-
ables JAKs to phosphorylate each other as well as specific
tyrosine motifs within the cytokine receptors. STATs that rec-
ognize these phosphortyrosine motifs are recruited to the
receptor, and after this they are activated by a JAK-depen-
dent tyrosine phosphorylation event. Upon activation, STATs
dissociate from the receptors, dimerize, and translocate to
the nucleus to bind to specific DNA sites and alter transcrip-
tion.21 Small molecules acting as JAK inhibitors are already
accepted as pharmaceutical solutions for a variety of autoim-
mune diseases.22 Among the cytokines the most prominent
family is the group of interleukins from IL-1 to IL-36. They
function in immune response in charge of the defense against
extracellular infections and contributing to the pathogenesis
of some autoimmune inflammatory diseases among them is
the dry eye disease.23–25 Cytokines, given their central role
in the pathogenesis of dry eye, are attractive targets for
treatment and a significant part of pharmacology research
is based on their use as anti-inflammatory agents. Eleven Bio-
therapeutics, Inc., is using IL-17 family cytokine compositions
as antagonists. The company is evaluating the proteins of
interest in a mouse model for dry eye disease. The dry eye
can be induced in mice by subcutaneous injection of
scopolamine and afterward the mice are placed in con-
trolled-environment chambers.26 This method concerns bind-
ing proteins, including non-naturally occurring and
recombinantly modified proteins that bind to an IL-17R and
including proteins having a mutated IL-17 cytokine sequence
(patent WO/2011/044563).27 Additionally the company is
studying methods of administering an IL-1 or IL-17 cytokine
for treating dry eye disorder. The antagonists can be admin-
istered topically using an ophthalmic composition to the eye
prior to sleep or nocturnal rest (patent WO/2011/163452).28
As a result of this research Eleven Biotherapeutics, designed
and engineered a novel and differentiated protein-based
bio-therapeutic for dry eye disease, called EBI-005, which is
the first IL-1 signaling inhibitor and is designed for topical
ocular administration. The company commenced Phase 1b/
2a clinical trials (ClinicalTrials.gov Identifier: NCT01748578)
and presented the results at the 7th international conference
Table 1. Drugs and properties.
Patent Company Properties
WO/2011/044563 Eleven
Biotherapeutics, Inc.
Recombinantly modified proteins that bind to an interleukin receptor IL-17R.
WO/2011/163452 Eleven
Biotherapeutics, Inc.
Administration of an IL-1 or IL-17 cytokine.
WO/2010/047500 Benebiosis Co. Ltd. Sialic acid and independent monosaccharide residues.
WO/2009/064983 Alcon Research, Ltd. Protease, inhibiting peptide substrates, a borate salt and a galactomannan.
WO/2009/114512 WO/2010/
039939 US20128158616
Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors.
WO/2010/085684 WO/2011/
017178 WO/2012/015972
Rigel
Pharmaceuticals Inc.
2,4-Substituted pyrimidinediamine compounds as JAK inhibitors.
WO/2009/089036 Schepens Eye
Research Institute
Physiological acceptable salt, poleaxes analogs with carpool, carpool/hydroxypropyl
methycellulose (HPMC), carpool-methyl cellulose, a mucolytic agent,
carboxymethylcellulose (CMC), hyaluronic acid, cyclodextrin, and petroleum.
WO/2010/124259 WO/2010/
124262
Allostera Pharma
Inc.
Allosteramers™ – short peptides that can effectively modulate TNF receptor activities.
WO/2009/048929 Lux Biosciences, Inc. Voclosporin a calcineurin inhibitor.
US20107772433
US20118080682
US20118110562
University of
Tennessee
Selective androgen receptor modulators (SARM) (a substituted acylanilide).
US20128158828 Gtx Inc. Selective estrogen receptor modulators (SERMs)
WO/2009/082437 Ligand
Pharmaceuticals Inc.
Selective androgen receptor modulators (SARMS).
WO/2010/092546 Consiglio Nazionale
Delle Ricerche
Selective androgen receptor modulator (non-steroidal propionanilide and hydantoine
structured compounds).
WO/2011/068786 Bridge Pharma, Inc. R-salbutamol – increasing meibomian gland secretion.
US20097585877 Acadia
Pharmaceuticals, Inc.
Selective androgen receptor modulators-aminophenyl derivatives.
WO/2008/153746 Aciex Inc. Acular (ketorolac tromethamine 0.5% ophthalmic solution) with a carboxymethyl
cellulose (CMC)-based artificial tear.
WO/2009/039461 WO/2010/
111353
Acadia
Pharmaceuticals, Inc.
Serotonin receptor agents-Serotonin or 5-hydroxytryptamine (5-HT).
WO/2009/051439 AmorePacific
Corporation
Modulator of the activity of calcium activated chloride channel.
WO/2011/106697 Schepens Eye
Research Institute
Anti-lymphangiogenic agent.
WO/2010/047681 WO/2010/
059894
Bridge Pharma, Inc. Norketotifen, a cycloheptathiophene compound.
WO/2010/146132 Cellzome Limited. ZAP-70 inhibitors, pyrimidine derivatives or sulfonamides and sulfamides or
heterocyclylaminopyrimidines.
WO/2011/034207 Senju
Pharmaceutical Co.,
Ltd.
A polypeptide having a partial sequence of lacritin
WO/2012/006083 University of Florida siRNAs delivery to the cell cytoplasm by endocytosis
WO/2013/096226 Sylentis S.A. SYL1001 siRNA to target Transient Receptor Potential Vanilloid 1 (TRPV1).
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onstrated positive clinical results and the dual action EBI-005
was capable to treat both the signs and symptoms of dry eye
disease. Based on these results, Eleven Biotherapeutics will
advance EBI-005 into a new pivotal efficacy and safety, mul-
ti-center clinical trial. Additionally the Korean company Bene-
biosis Co., Ltd., and the Korean University of Sungkyunkwan
are developing a compound comprised of sialic acid and
independent monosaccharide residues (patent WO/2010/
047500).29 The compound suppresses the expression of the
enzyme matrix metallopeptidase 9 (MMP-9), encoded by
the MMP9 gene30 and the inflammation causing cytokines
IL-1b and tumor necrosis factor-alpha (TNF-a) on corneal epi-
thelial cells. The compound suppresses as well the activity of
the vascular endothelial growth factor VEGF-mediated VEG-
FR-2 on human retinal endothelial cells, possibly is involved in
enhanced angiogenesis of the Sjögren’s syndrome.31 It is
possible that this compound may also have a potential role
in other ocular disorders with neovascularization. Another
MMP-9 inhibitor is invented by Alcon Research, Ltd. The
compound under development is a gelatin ophthalmic com-
position containing protease, inhibiting peptide substrates,a borate salt and a galactomannan (polysaccharides derived
from natural gums) (patent WO/2009/064983).32 The
inhibiting peptide substrate is normally consisting of gelatin,
alpha-2-macroglobulin, ovomacroglobulin, collagen and
casein and after a topical administration is inhibiting the pro-
tease MMP-9. Nagelhout and colleagues suggested that ele-
vated levels of MMP-9 and cytokines IL-1beta, IL-8, and TGF-
beta1 were detected in the lacrimal gland and cornea of dry
eye model rabbits.33 Tear composition in dry eyes, or dys-
functional tear syndrome, may destabilize the tear film and
cause ocular surface epithelial disease. Increased activity of
matrix metalloproteinases (MMPs), especially MMP-9, plays
a critical role in wound healing and inflammation and is pri-
marily responsible for the pathologic alterations to the ocular
surface that leads to a dysfunctional tear state.34 Furthermore
Incyte Corporation is developing azetidine and cyclobutane
derivatives as JAK inhibitors for the treatment of dry eye
(patents WO/2009/114512,35 WO/2010/03993936 and US20
128158616).37 The inhibitors under development are hetero-
aryl substituted pyrrolo 2,3-b pyridines and heteroaryl substi-
tuted pyrrolo 2,3-b pyrimidines (Fig. 1a) and (Fig. 1b)
modulating the JAK kinase activity, able to bind and increase
Figure 1a. Heteroaryl substituted pyrrolo 2,3-b pyridine.
Figure 1b. Heteroaryl substituted pyrrolo 2,3-b pyrimidine.
22 B. Colligris et al.or decrease the activity of one or more members of the JAK
family of kinases by influencing IL-6 and STAT3 signaling.38
The JAKs modulated could be of the type JAK1, JAK2,
JAK3 or non-receptor tyrosine-protein kinase 2 (TYK2). The
administration of the inhibitor may be systemic or topical.
The dosage form is containing from about 5 to about
1000 mg, of the active ingredient. The compound was tested
to animal preclinical models including the rabbit Concanava-
lin A (ConA) lacrimal gland model, the scopolamine mouse
model (subcutaneous or transdermal) and the Botulinum
mouse lacrimal gland model. Similarly Rigel Pharmaceuticals
Inc. is developing 2,4-substituted pyrimidinediamine com-
pounds (Fig. 1c) as JAK inhibitors for the treatment of dry
eye disease (patents WO/2010/085684,39 WO/2011/
01717840 and WO/2012/015972.41 These compounds are po-
tent and particularly selective inhibitors for cytokine signaling
pathways containing JAK2 and JAK3 and it may be used to
regulate or inhibit JAK kinase activity in the signaling cas-
cades in which JAK kinases play a role and the biological re-
sponses are affected by such signaling cascades. It is
considered that the compounds can be used to inhibit JAK
kinase, either in vitro or in vivo, in a vast variety of cell types
expressing the JAK kinase. They may also be used to regulate
signal transduction cascades in which JAK kinases, particu-
larly JAK3, play a role. The JAK-dependent signal transduc-Figure 1c. 2,4-substitutetion cascades are including the signaling cascades of
cytokine receptors involved in the common gamma chain,
such as, IL-4, IL-7, IL-5, IL-9, IL-15 and IL-21, or IL-2, IL-4, IL-
7, IL-9, IL-15 and IL-21 receptor signaling cascades. Accord-
ing to the company the inhibitor could achieve beneficial clin-
ical results by preventing the disease from occurring in a
patient that is predisposed or does not yet display symptoms
of the disease. The compound is relatively potent compared
to other similar inhibitors and can be administered at low
doses locally, thus minimizing systemic adverse effects. The
administration of one or more of the class of 2,4-pyrimidined-
iamine compounds once daily to most twice a day, is effective
to increase tear production volume as compared to un-
treated tear production volume and diminish the symptoms
of dry eye syndrome. The tear production volume is in-
creased within two to five days at about 25% to 50% over ini-
tial tear production. The increase in tear production upon
administration results, in some instances, is comparable to
normal tear production. In the same direction Schepens Eye
Research Institute (patent WO/2009/089036)42 is developing
a composition which is inhibiting the function of the inflam-
matory cytokine IL-17 that acts as a potent mediator to
inflammatory processes.43,44 The composition was designed
to treat IL-17-mediated ocular inflammatory disorders and
comprises of a compound containing a physiologically
acceptable salt, poleaxes analogs with carpool, carpool/
hydroxypropyl methycellulose (HPMC), carpool-methyl cellu-
lose, a mucolytic agent, carboxymethylcellulose (CMC), hyal-
uronic acid, cyclodextrin, and petroleum. The compound is
locally administered to the patient eye, inhibiting the activity
of the inflammatory IL-17 cytokine thus reducing the severity
of the dry eye syndrome. The IL-17 receptor expression on
ocular surfaces was analyzed using immunofluorescence
microscopy. According to Schepens Institute, during the
evaluation of the compound a significant decrease in the
intensity of clinical signs of dry eye which was measured by
corneal fluorescein staining (CFS) scoring, during the induc-
tion as well as the progression phases of the disease in the
anti-IL-17 antibody-treated group was noticed. Finally Allos-
tera Pharma Inc. is working on the discovery that short pep-
tides based on amino acid sequences of extracellular or
transmembrane regions of a tumor necrosis factor (TNF)
receptor are effective in modulating TNF receptor activities
(patent WO/2010/12425945 and WO/2010/124262).46 A tu-
mor necrosis factor receptor, or death receptor, is a trimeric
cytokine receptor that binds to TNF. The company is devel-
oping new and more effective therapeutic compositions
called Allosteramers™ for treating inflammatory diseases
associated with TNF or TNF receptor dysfunction. The Allos-
teramers™ are short peptides that can effectively modulate
TNF receptor activities based on amino acid sequences of
extracellular or transmembrane regions of a TNF receptor.
The short peptide is composed of 5–25 amino acids and is
derived from body’s own proteins that can interact with thed pyrimidinediamine.
Figure 2a. Voclosporin.
Figure 2b. Substituted acylanilide.
Figure 3a. 4-Methoxy-N,N-bis-(4-methoxyphenyl)-benzamide.
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teins, without competing with a natural ligand. Such effective
modulators can be designed simply based on linear amino
acid sequences of a biological target without first character-
izing any secondary or tertiary structure of the target.47
Calcineurin and mTOR inhibitors
Tzu and colleagues demonstrated that adequate topical
immunomodulation using topical calcineurin inhibitors may
eliminate the need for steroids and favorably alter the long-
term prognosis of patients with inflammatory ocular surface
diseases.48 Calcineurin inhibitors are potent immunosuppres-
sants that reversibly inhibit T-cell proliferation and prevent
the release of pro-inflammatory cytokines by blocking the
activity of calcineurin, a ubiquitous enzyme that is found in cell
cytoplasm. Calcineurin inhibitors can be highly effective in im-
mune-mediated ophthalmic diseases such as uveitis, dry eye
syndrome and inflammatory blepharitis.49 Lux Biosciences,
Inc. is developing an ophthalmic composition called Voclospo-
rin (VCS, ISA247) (patent WO/2009/048929)50 (Fig. 2a).
Voclosporin is a novel calcineurin inhibitor, developed usinga pharmacodynamic approach for use in solid organ transplan-
tation and autoimmune disease. The compound is useful for
inflammatory ocular surface diseases selected from the group
consisting of dry eye syndrome, Sjögren’s syndrome, uveitis,
conjunctivitis, keratitis, keratoconjunctivitis, vernal keratocon-
junctivitis, atopic keratoconjunctivitis, and autoimmune
disorders of the ocular surface, including cicatrizing conjuncti-
vitis, blepharitis, and scleritis.Androgen and estrogen receptor inhibitors
Since some years there is growing evidence that sex
hormones play a key role in the formation and course of
dry eye disease and thus provide potentially promising
approaches for therapy. There is growing evidence on the
Figure 3b. 4-(2(jR)-(l(5)-hydroxyl-2,2J2-trifluoroethyl)pyrrolidinyl)-2-trifi-
uoromethyl-benzonitrile.
24 B. Colligris et al.relationship between androgens, estrogens, and progester-
ones on one hand and the lacrimal and Meibomian glands
on the other.51 Most women who suffer from dry eye syn-
drome are post-menopausal however, not all post-meno-
pausal women develop dry eye, suggesting that other
factors, in addition to the decrease in ovarian hormones,
are necessary for the development of the disease. Mostafa
and colleagues demonstrated after in vivo experiments that
lymphocytic infiltration preceded lacrimal gland apoptosis
after ovariectomy and removal of ovarian sex hormones
accelerated these effects in the genetically predisposed ani-
mals. These effects were more severe and persistent com-
pared to control animals. In addition, sex hormone
replacement at physiological levels prevented these symp-
toms. Still we are not clear about the mechanisms by which
decreased levels of sex hormones caused lymphocytic infil-
tration and apoptosis and the interaction of lack of sex hor-
mones with the genetic elements.52 In this sense the
University of Tennessee is developing a series of selective
androgen receptor modulators (SARM) (a substituted acylan-
ilide) (Fig. 2b) as potential agents for treatment of dry eye
disease (patents US20107772433,53 US20118080682,54
US20118110562).55 The compounds are non-steroidal li-
gands for the androgen receptor and exhibit androgenic
and/or anabolic activity. They are partial agonists or partial
antagonists in a tissue selective manner, which allows for tis-
sue-selective androgenic and/or anabolic effects. These
agents may be active alone or in combination with progestins
or estrogens, or other agents. Furthermore Gtx Inc. is work-
ing with a novel class of selective estrogen receptor modula-
tors (SERMs) for the treatment of dry eye syndrome
containing 4-methoxy-N,N-bis-(4-methoxyphenyl)-benzam-
ide (patent US20128158828)56 (Fig. 3a). The nuclear hormoneFigure 4a. Propreceptor superfamily of ligand activated transcription factors
is present in various tissues, and responsible for a multitude
of effects in these tissues. The nuclear receptor (NR) super-
family presently comprises approximately 48 different pro-
teins, most of which are believed to function as ligand
activated transcription factors, exerting widely different bio-
logical responses by regulating gene expression. Members
of this family include receptors for endogenous small, lipo-
philic molecules, such as steroid hormones, retinoids, vitamin
D and thyroid hormone. Members of the steroid nuclear
receptor sub-family exhibit significant homology to each
other and possess closely related DNA and ligand binding
domains. Given the close similarity in ligand binding domains
of the steroid nuclear receptors, it is not surprising that many
naturally occurring and synthetic molecules possess the abil-
ity to modulate the activity of more than one steroid nuclear
receptor. Similarly Ligand Pharmaceuticals Inc. is developing
a series of selective androgen receptor modulators (SARMS)
(patent WO/2009/082437)57 (Fig. 3b). The compound
4-(2(jR)-(l(5)-hydroxyl-2,2J2-trifluoroethyl)pyrrolidinyl)-2-trifiuo-
romethyl-benzonitrile is binding to androgen receptors and
modulate the activity of androgen receptors and could be
agonists, antagonists, partial antagonists or receptor modu-
lators. Equally the Institute Consiglio Nazionale Delle Ricer-
che is developing androgen receptor modulating nuclear
hormone receptor binding compounds useful in the treat-
ment of nuclear receptor, especially the steroid receptor,
and in particular the androgen receptor (AR). The agents
are novel non-steroidal propionanilide with hydantoine
(Fig. 4a) and bicalutamide (Fig. 4b) structured compounds
having utility as tissue-selective androgen receptor modula-
tors (SARM) (patent WO/2010/09254658 and WO/2010/
116342).59 These agents are a new class of androgen recep-
tor compounds demonstrating anti-androgenic and andro-
genic activity of a non-steroidal ligand of the androgen
receptor. Similarly Bridge Pharma, Inc. is developing R-salbu-
tamol (Fig. 4c) which is increasing meibomian gland secretion
(patent WO/2011/068786).60 R-salbutamol is administered
by instillation to the eye or into the conjunctival sac. may also
be instilled into the nose via nose drops, nasal sprays, or na-
sal insufflation of dry powder containing R-salbutamol. Alter-
natively, R-salbutamol may be administered systemically,
such as by the oral, intravenous or transdermal routes or by
inhalation. Upon systemic administration, the active com-
pound will reach the ocular tissues after systemic absorption
and distribution. Although a beta-2 agonist, such as R-salbu-
tamol, may have ocular therapeutic activity after systemic
administration, it is a preferred method to administer drug
formulations topically to the eye, for example as solutions,
gels, ointments, emulsions, sprays, washes or as topical
liposome formulations or as implantable devices that
are releasing the beta-2 agonist in a controlled manner.ionanilide.
Figure 4b. Bicalutamide.
Figure 4c. R-salbutamol.
Figure 4d. Aminophenyl.
Figure 5a. Ketorolac tromethamine.
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vices, such as for example pump-catheter systems, continu-
ous ocular release devices or via contact lenses or ocular
mini-tablets or gel-forming ocular mini-tablets that contain
the active medication. Furthermore, Acadia Pharmaceuticals,
Inc. is developing a novel class of aminophenyl (Amino phe-
nyl) (Fig. 4d) derivatives as selective androgen receptor mod-
ulators (patent US20097585877).61 The method of treating
xerophthalmia comprises of administering this compound or
a prodrug, stereoisomer, or pharmaceutically acceptable salt.Non-steroidal anti-inflammatory drugs
The dry eye syndrome tends to be accompanied by ocular
surface inflammation and the use of anti-inflammatory agents
is beneficial for the patients. As no diagnostic tests are avail-
able to assess ocular surface inflammation severity, the right
timing to launch an anti-inflammatory agent is difficult to
determine. Patients with mild intermittent symptoms which
can be alleviated with ophthalmic lubricants do not typically
require anti-inflammatory therapy and this type of therapy
has to be considered as last resource. Anti-inflammatory
treatment of dry eye syndrome may include short-term corti-
costeroids, Cyclosporine A emulsion, oral tetracycline ther-
apy, oral omega-3 fatty acid supplements, and autologous
serum eye drops. Alternatives to corticosteroids should be
considered when long-term treatment is required for an ocu-
lar surface condition as severe side effects were noticed after
prolonged use of corticosteroids. A typical solution is the use
of Non-steroidal anti-inflammatory drugs (NSAIDs). In this
sense the company Aciex Inc. is developing ophthalmic for-mulations comprised of one or more components of a tear
substitute and a low dose amount of non-steroidal anti-
inflammatory drugs (NSAID) effective to increase tear film
break up time (TFBUT) and the ocular protection index
(OPI), as well as decrease ocular discomfort, treating and pre-
venting signs and symptoms associated with dry eye disease
(patent WO/2008/153746).62 The compound under develop-
ment is comprised of Acular (ketorolac tromethamine
(Fig. 5a) 0.5% ophthalmic solution) with a carboxymethyl cel-
lulose (Fig. 5b) (CMC)-based artificial tear.
Serotonin receptor inhibitors
Acadia Pharmaceuticals, Inc. is developing N-substituted
piperidine derivatives (Fig. 6a) as serotonin receptor agents
(patent WO/2009/03946163 and WO/2010/111353).64 Seroto-
nin or 5-hydroxytryptamine (5-HT) plays a significant role in
the functioning of the mammalian body. In the central nervous
system, 5 -HT is an important neurotransmitter and neuromod-
ulator that is implicated in such diverse behavior and responses
as sleeping, eating, locomotion, perceiving pain, learning and
memory, controlling body temperature and blood pressure. In
the spinal column, serotonin plays an important role in the con-
trol systems of the afferent peripheral nociceptors.65 Peripheral
functions in the cardiovascular, hematological andgastrointesti-
nal systems have also been ascribed to 5-HT. 5-HT has been
found to mediate a variety of contractile, secretory, and electro-
physiological effects including vascular and nonvascular smooth
muscle contraction, and platelet aggregation.66 The 5-HT2 A
receptor subtype (also referred to as subclass) is widely yet
discretely expressed in the human brain.
Calcium activated chloride channel modulators
AmorePacific Corporation is developing (patent WO/
2009/05143967 a method of identifying agents which
modulate the activity of calcium activated chloride channel.
Figure 5b. Methylcellulose.
Figure 6a. N-substituted piperidine.
Figure 6b. Norketifen.
26 B. Colligris et al.The method consists of identifying an agent which modulates
an activity of a protein, wherein the protein is represented by
the amino acid sequence or has at least 90% amino acid se-
quence identity and transports chloride ions across a cell
membrane, comprising: (a) exposing cells which express the
protein to the agent; and (b) measuring degree of chloride
ion transport in the exposed cells, wherein a change in the
degree of chloride ion transport is compared to control cells,
which express the protein but not exposed to the agent, is
indicative of an agent capable of modulating an activity of
the protein. The agents identified by this method can beused for the prevention or treatment of xerophthalmia
caused by the dysfunction of calcium activated chloride
channel.Anti-lymphangiogenic agent
There is growing evidence of corneal lymphangiogenesis
in dry eye disease. Sunali et al. demonstrated that there is
evidence of selective growth of lymphatic (but not blood)
vessels in dry eye, providing new insights into the pathogen-
esis of the disease. These findings suggest that these newly
formed corneal lymphatic vessels may serve as potential con-
duits for migration of corneal APCs to lymphoid tissues,
where they generate auto-reactive TH17 and TH1 cells in
dry eye. This study not only provides a link between ocular
surface inflammation and the generation of T-cell-mediated
immunity in the lymphoid compartment but also offers an
example of how lymphangiogenesis and hemangiogenesis
can be naturally dissociated in a pathologic state. The sever-
ing of the ‘‘eye-lymphatic axis’’ in other immune-mediated
conditions, such as transplant rejection, has been shown to
hold promise as a strategy for suppressing alloimmunity with-
out inhibiting needed innate host defense mechanisms.
Similarly, a strategy targeting prolymphangiogenic factors,
such as VEGF-C and VEGF-D, may prove effective in improv-
ing dry eye.68 Schepens Eye Research Institute developed a
Figure 7a. Pyrimidine derivative.
Figure 7b. Sulfonamides and sulfamides.
Figure 7c. Heterocyclylaminopyrimidines.
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comprising administration of an anti-lymphangiogenic agent
to the human patient (patent WO/2011/106697).69 Prefera-
bly, the amount of the anti-lymphangiogenic agent employed
is effective to inhibit the binding of VEGF-C and/or VEGF-D
ligand to VEGFR-3 or the stimulatory effect of VEGF-C and/
or VEGF-D on VEGFR-3. Targeting prolymphangiogenic
growth factors or their receptors could inhibit the trafficking
of antigen-presenting cells to the draining lymph nodes and
hence prove to be a potential therapeutic target for dry
eye disease.70Cycloheptathiophene
Bridge Pharma, Inc. is developing Norketotifen a cyclo-
heptathiophene compound for the treatment of xerophthal-
mia (patent WO/2010/04768171 and WO/2010/059894)72
(Fig. 6b). Norketotifen, is a de-methylated metabolite of
ketotifen, which is a potent antimalarial drug.73 Ketotifen
blocks histamine H1 receptors, stabilizes mast cells, and pre-
vents eosinophil accumulation. While ketotifen was found not
to increase tear flow after topical administration to the eye,
norketotifen was found to increase tear flow after topical
administration to the eyes of laboratory animals. Topical ocu-
lar formulations of norketotifen preferably contain norketoti-
fen in concentrations between 0.01% and 0.50% and
preferred osmolality between 150 and 450 mOsm. The ocular
formulation could contain combinations of norketotifen and
cyclosporine in concentrations between 0.01% and 0.1%.
The drug could be administered as ocular solution, ocular
hydrophilic ointment and gel, ocular hydrophobic ointments
ocular emulsion and ocular liposome formulation, all contain-
ing norketotifen. The formulation could allow for once-daily
ocular administration and for repeated ocular administrations
from two to five times daily to patients.ZAP-70 inhibitors
The company Cellzome Limited is developing a series of
ZAP-70 inhibitors. These inhibitors could be pyrimidine deriv-
atives (patent WO/2010/142766)74 (Fig. 7a), sulfonamides
and sulfamides (patent WO/2010/146132)75 (Fig. 7b) or het-
erocyclylaminopyrimidines WO/2010/14613376 (Fig. 7c).
ZAP-70 is a protein tyrosine kinase and its lack of expression
is associated with an immunodeficiency. ZAP-70 is situated at
the crossroad of several signaling pathways that control T
lymphocyte development and function. Recent studies are
associating abnormal ZAP-70 expression with pathological
conditions. Mouse models also revealed that partial defects
in ZAP-70 activity can be associated with autoimmunity and
that ZAP-70 is involved between immunity and tolerance.77
Several reports provided genetic evidence that ZAP-70 plays
an important role in T cell activation. Mutations in ZAP-70
have been shown to be responsible for an autosomal reces-
sive form of severe combined immunodeficiency syndrome
(SCID) in humans.78 This SCID syndrome is characterized by
the absence of peripheral CD8+ T cells and by the presence
of circulating CD4+ T cells that do not respond to TCR-med-
iated stimuli in vitro. Targeted disruption of the ZAP-70 gene
in mice leads to defects in thymic development and T cell
activation.79 Inhibitors of ZAP-70 may therefore represent
drugs useful for the treatment of diseases of the immune
system such as dry eye disease.Partial peptide of lacritin
Senju Pharmaceutical Co., Ltd. is developing a polypep-
tide having a partial sequence of lacritin, which promotes
adhesion between a cell and extracellular matrix, claimed
to be superior in stability in aqueous solution (patent WO/
2011/034207).80 The polypeptide is containing an amino acid
sequence which is a particular partial sequence of lacritin and
characterized by pyro-modification of N-terminal glutamine.
Since the polypeptide promotes adhesion between a cell
Figure 8. TRPVl antagonists.
28 B. Colligris et al.and extracellular matrix, and is stable in aqueous solution, it
can provide good preservation stability. Eye drops contain-
ing lacritin are likely to be useful in the treatment of ocular
diseases such as dry eye syndrome, Sjögren’s syndrome,
and corneal epithelial wounds. The polypeptide is particularly
useful for the treatment of a corneal epithelial disorder asso-
ciated with these diseases. In addition, it has a promoting ac-
tion of tear fluid secretion from lacrimal gland acinar cells.
Only a handful of tear proteins appear to be selectively
down-regulated in dry eye. Lacritin and lipocalin-1 are two
tear proteins selectively deficient in dry eye. Both proteins
influence ocular surface health. Lacritin is a pro-secretory
mitogen that promotes basal tearing when applied topically.
Levels of active monomeric lacritin are negatively regulated
by tear tissue transglutaminase, whose expression is elevated
in dry eye with ocular surface inflammation. Lipocalin-1 is the
master lipid sponge of the ocular surface, without which
residual lipids could interfere with epithelial wetting. It also
is a carrier for vitamins and steroid hormones, and is a key
endonuclease. Accumulation of DNA in tears is thought to
be pro-inflammatory. Functions of these and other tear pro-
teins may be influenced by protein–protein interactions. Here
we discuss new advances in lacritin biology and provide an
overview on lipocalin-1, and newly identified members of
the tear proteome.81RNA interference
RNAi consists of highly efficient selective and specific
inhibition of gene expression. RNAi is mediated by small
fragments of double-stranded RNA, consisting of 19–23
nucleotides, which promote degradation of messenger
RNA (mRNA), thus inhibiting synthesis of the proteins for
which they code and which are responsible for the pathology.
RNAi therapy has great potential as this mechanism is used
naturally by cells to regulate gene expression in a way that
is both non-toxic and highly effective. The University of Flor-
ida is developing compositions and methods for the delivery
of siRNAs to the cell cytoplasm by endocytosis (patent WO/
2012/006083).82 The compositions comprise molecular con-
jugates between a receptor ligand, most suitably a small mol-
ecule ligand and an siRNA that when administered to a
patient, can modulate or relieve symptoms of dry eye disease
as well as inhibiting or reducing such cellular processes as
apoptosis of glandular acinar cells that trigger or sustain
Sjögren’s Syndrome. The siRNA moiety can reduce cas-
pase-3 levels when delivered to a salivary or lacrimal cell.
The method for delivery of a molecular conjugate to a cell,
comprises the steps of contacting with a cell with a molecular
conjugate comprising a ligand characterized as having affin-
ity for a surface receptor of the cell, and an siRNA moietylinked to the ligand; and maintaining the cell, or population
of said cells, under conditions whereby the ligand specifically
binds to a surface receptor of the cell or cells, whereupon the
molecular conjugate enters the cell or cells by endocytosis,
thereby delivering the siRNA moiety to the cytoplasm of
the cell or cells. Similarly the Spanish company Sylentis S.A.
is developing SYL1001 a new chemical specifically designed
to target the Transient Receptor Potential Vanilloid 1 (TRPV1)
(patent WO/2013/096226).83 (Fig. 8). This nociceptor is in-
volved in pain stimuli transmission. The company started on
November 2012 Phase I/II clinical trials for its compound
named SYL1001 (ClinicalTrials.gov Identifier: NCT01776658)
with ocular topical administration of SYL1001 for 10 consec-
utive days on 60 patients were performed. SYL1001 DP is
administered in the form of eye drops for treating or prevent-
ing eye discomfort associated with dry eye and with corneal
injuries, with a view to minimizing pain and improving pa-
tients’ quality of life. SYL1001 eye drops is a sterile, isotonic
saline solution presented in single-dose vials, eliminating
the need for antimicrobial preservatives.84 According to re-
sults published for Phase I clinical trials (ClinicalTrials.gov
Identifier: NCT01438281) local tolerance was excellent with
no serious adverse events reported and no modifications of
the ocular surface or iris detected. The analytical results at
final examination did not show differences from those
observed during selection. Pharmacokinetic results indicated
that no levels of siRNAs were detected above LOOQ (40 ng/
mL) in any of the subjects. These results were expected as
SYL1001 which is a non-modified siRNA, with a low stability
in plasma (half-life is less than 5 min) (ARVO 2012).85Concluding remarks
Current topical treatments for dry eye patients include the
use of lubricants and anti-inflammatory drugs. However,
lubricants only suppress negative symptoms temporarily,
and chronic use of topical steroids is related to severe ocular
side effects such as cataract and glaucoma. Further research
is necessary toward the action mechanisms of new mucin and
tear secretagogues compounds possibly possessing anti-
inflammatory properties. Additionally further research is
needed on understanding the immunomodulatory and
inflammatory mechanisms of the conjunctiva.
The deeper understanding of the cellular mechanisms
implicated in dry eye is necessary not only to improve symp-
toms but also to restore the homeostasis of the ocular
surface. The pursuit of effective dry eye treatment strategies
is delayed by the absence of an accepted set of definitive
criteria for evaluating disease severity. There is a lack of
an objective test for the diagnosis of the severity of the
disease, because symptoms’ evaluation is insufficient as a
Recent developments on dry eye disease treatment compounds 29measurement factor. There are several proposals for a novel
objective testing such as molecular markers86,87 or evaluation
of the tear film osmolarity88,89 but for the moment none of
them advanced after the pre-clinical test.Conflict of Interest
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